BRINGING THE FUTURE INTO FOCUS
Focused ultrasound is a breakthrough non-invasive treatment. Much like a magnifying glass focusing multiple beams of light on a single point, focused ultrasound concentrates intersecting beams of ultrasound energy deep in the body, with extreme precision, on a target as small as a grain of rice. As individual beams pass through healthy tissue, there is no effect. But at the focal point, the ultrasound energy results in biological effects that create the possibility to treat a variety of medical disorders.

Focused ultrasound procedures are performed in conjunction with real-time imaging to precisely target and track the treatment. Treatments usually take place in an outpatient setting without general anesthesia or incisions, resulting in minimal pain and discomfort and a more rapid recovery.

**A NEW SOLUTION**

**THE FOUNDATION SETS ITS SIGHTS ON MAKING A DIFFERENCE**

The Focused Ultrasound Foundation was created to improve the lives of millions of people worldwide by accelerating the development and adoption of focused ultrasound therapies. As a unique, philanthropic organization, the Foundation works to clear the path to ensure that focused ultrasound finds its place as a mainstream therapy for a range of serious medical conditions within years, rather than decades. Since its establishment in 2006, the Foundation has become the largest non-governmental source of funding for focused ultrasound research.

We’re working to bring this vision of the future into focus in the fastest time possible.

**WILL YOU JOIN US?**

We see a future where...

- Brain tumors are treated without cutting into the skull
- Cancer is destroyed without harmful radiation
- Depression, untreatable by medication, is relieved with a simple procedure
Dear Friends,

In 2014, the field’s momentum was tangible. Research breakthroughs allowed us to visualize focused ultrasound improving countless lives of patients with life-threatening or disabling conditions. Strides were made in tackling challenging neurological conditions like brain tumors and Parkinson’s disease, creating the possibility for a new non-invasive treatment alternative. Promising results for obsessive-compulsive disorder have fostered hope for many psychiatric indications. The technology earned a place in the pediatric arena, treating a teenager’s painful bone tumor, enabling him to enjoy sports and activities again.

While research is opening up new possibilities, focused ultrasound is far from being a standard of care. More research must be done, more resources must be applied, and more barriers must be overcome.

The Foundation’s efforts toward the cause have made real progress, and it is due to our generous donors who have helped us advance this innovative technology. With your help, we are able to keep our eye trained on the target – a future where focused ultrasound is available to help your friends, your family, and yourself.

Be well,
Neal F. Kassell, MD

The Foundation has focused its resources and efforts on select strategic initiatives designed to maximize our impact and energize innovation around this revolutionary technology.

**FIVE STRATEGIC INITIATIVES**

- CREATE KNOWLEDGE
  - Accelerating research, setting priorities, and influencing the field

- CONVENE THE COMMUNITY
  - Catalyzing the field through collaboration

- OVERCOME BARRIERS
  - Closing the gap to patient use

- CULTIVATE THE NEXT GENERATION
  - Fostering promising researchers and students

- INCREASE AWARENESS
  - Spreading knowledge within the community and around the world

**SETTING OUR SIGHTS ON SUCCESS**

- 23 ARTICLES PUBLISHED in the Journal of Therapeutic Ultrasound
- 1st pediatric treatment in North America
- 55 conditions being researched
- 14 research projects funded
- 1st malignant brain tumors treated
- More than 400 attendees from 24 countries at the 2014 Symposium
- 76 PATIENTS enrolled in essential tremor pivotal trial
- 76 PATIENTS enrolled in essential tremor pivotal trial
- More than 400 attendees from 24 countries at the 2014 Symposium
- 76 PATIENTS enrolled in essential tremor pivotal trial
- 55 conditions being researched
STATE OF THE FIELD

GLOBAL RESEARCH
Tackling gateway diseases

Focused ultrasound is an early-stage technology, with groundwork being laid across the field by dedicated researchers at more than 160 centers around the world, progressing from technical research to clinical trials on the path toward widespread access. In 2014, global research made strides, helping to establish focused ultrasound’s potential to treat many more diseases, including cancers and psychiatric disorders.

BREAST TUMORS

A study at the University of Virginia is paving the way for non-invasive breast treatment. In an early-stage trial, researchers are assessing focused ultrasound to destroy common benign breast lumps. If it is successful, then a larger multicenter trial will be conducted. This research is an important stepping stone to the ultimate goal of treating breast cancer tumors.

PSYCHIATRIC DISORDERS

Early results in a 12-patient Korean study support the potential of focused ultrasound to treat disabling obsessive-compulsive disorder (OCD). The first four patients had the targeted areas of the brain treated without complications or side effects. The procedure resulted in gradual improvement in their OCD, depression, and anxiety. Researchers are planning a depression trial in the coming year, suggesting a potential non-invasive option for treating various psychiatric disorders.

“Using focused ultrasound, we were able to reduce the symptoms for these OCD patients and help them get some of their life back without the risks or complications of the more invasive surgical approaches that are currently available.”

–Dr. Jin Woo Chang

SOFT TISSUE TUMORS

Researchers at Stanford are reporting promising initial results in a study with five patients exploring the use of focused ultrasound to destroy soft tissue tumors in the extremities. In April, they reported that focused ultrasound resulted in an average of 63% of the patients’ tumors eliminated after one or two treatments. This research is leading to plans for a larger study and may open the door to treating other types of tumors.

GLOBAL RESEARCH
Tackling gateway diseases

MORE THAN 50 MEDICAL CONDITIONS ARE IN VARIOUS STAGES OF R&D AND COMMERCIALIZATION AROUND THE WORLD.

TREATMENTS WORLDWIDE TO DATE

STUDY CANCES 15,000
PROSTATE CANCER 11,000
UTERINE FIBROIDS 22,580
LIVER CANCER 15,000
BONE METASTASES 7,500
BREAST CANCER 16,000
OTHER 1,430

OCD STUDY PROMISING FOR PSYCHIATRIC DISORDERS
CREATE KNOWLEDGE
Accelerating research, setting priorities, and influencing the field

The Foundation’s research program enjoyed a year of firsts in 2014. From neurological advances to cancers and pediatrics, our research funds helped fuel significant progress.

PARKINSON’S DISEASE
The year began with a major milestone: the first treatment in a study assessing focused ultrasound for dyskinesia in Parkinson’s disease. The treatment was performed in Korea as part of a 20-patient pilot study funded by the Foundation and the Michael J. Fox Foundation. This study builds on experience gained during Foundation-funded pilot trials for essential tremor and Parkinsonian tremor.

ESSENTIAL TREMOR
Following years of research supported by the Foundation, enrollment is now complete in the international pivotal trial treating 76 patients with essential tremor. Patients will be followed for a year to assess the ability of focused ultrasound to reduce debilitating tremor. This study is the last step in generating data to support approval by the FDA.

BRAIN TUMORS
In March, focused ultrasound was used for the first time through the intact skull to destroy a portion of a recurrent brain cancer. The treatment was performed as part of an ongoing study in Switzerland. Building on this momentum, focused ultrasound was first used on a metastatic brain tumor in October. In a pilot study, neurosurgeons at Swedish Neurological Institute in Seattle destroyed a portion of a tumor deep within the patient’s brain without complications. This study, supported by the Foundation’s Keller Memorial Fund, is a small but essential step towards non-invasive treatments for a variety of brain tumors.

FIRST PEDIATRIC PATIENT TREATED IN NORTH AMERICA
Doctors at The Hospital for Sick Children in Toronto used focused ultrasound to eliminate a teenager’s disabling pain from an osteoid osteoma, a rare and at times debilitating benign bone tumor that occurs most commonly in males ages 10 to 35.

“I can do more things now that I couldn’t do before without getting a jolt of pain.”
–Jack

“For us, it was an overnight success.”
–Robin, Jack’s mom

MULTIPLYING IMPACT
In its nine years, the Foundation has invested $8.9 million in research, including $2.7 million to fund investigator-initiated research projects through a peer-reviewed process. Of the $4.7 million granted to 47 projects completed to date, 10 of these have received follow-on funding totaling $22.5 million, more than four times the return on our donors’ investment.

In 2014, the Foundation granted 12 awards totaling $1.3 million for research on conditions including pediatric bone disorders, lower back pain, thyroid cancer, osteoarthritis, and multiple sclerosis.
CONVENE THE COMMUNITY
Catalyzing the field through collaboration

The Foundation brings together leaders in the field by organizing meetings and symposia to report on research, share ideas and forge new partnerships.

WORKSHOP EXPLORES MODIFYING NEURAL ACTIVITY

A group of 24 researchers from academia, industry, government, and the Foundation spent two days in March discussing focused ultrasound’s use in neuromodulation. By stimulating or suppressing brain activity, focused ultrasound could enable a range of therapeutic benefits, including targeting regions of the brain for procedures, suppressing epileptic seizures or psychiatric symptoms, producing reversible nerve blocks to treat pain, and brain mapping.

The workshop proved vital in furthering progress by charting a course toward the first clinical use of FUS-induced neuromodulation.

CANCER CENTER OF EXCELLENCE OPENS IN LONDON

In September, the Foundation, the Institute of Cancer Research, the Royal Marsden, and Philips Healthcare celebrated the Center’s grand opening and the start of a clinical trial for bone metastases. This public/private collaboration is a model for translating the science of focused ultrasound into cancer clinical practice.

SYMPOSIUM DRAWS RECORD CROWD

The Foundation’s 4th International Symposium on Focused Ultrasound, held in October 2014, served as an important forum for sharing data, fostering collaboration, and incubating new ideas among more than 400 clinicians, scientists, industry leaders, and government representatives from around the world. An unprecedented 200+ presentations were given on the utilization of focused ultrasound for brain disorders, cancer, pain management, and other emerging applications. The Symposium is held biennially, and the next one is slated for August 2016.

“...This symposium offers a chance to see how focused ultrasound is being used in other fields of medicine and gives a broad view to the researcher and clinician. This is essential to pushing acceptance of therapeutic ultrasound as an emerging technology.”

– Attendee
INCREASE AWARENESS
Spreading knowledge within the community

As the world’s leading source of focused ultrasound information, the Foundation works tirelessly to glean and disseminate news of the field around the world. This year, we debuted a new website and newsletter, while bolstering social media efforts.

FOCUSED ULTRASOUND AND THE FUTURE OF HEALTHCARE

The Foundation serves as a thought leader by publishing bylined articles in agenda-setting media. We illuminate how new technologies like focused ultrasound can provide the superior outcomes, improved population health, and cost savings demanded by today’s healthcare systems.

TONY AND JONNA MENDEZ SPEAK OUT

At the Foundation’s 2014 symposium, former CIA spymaster and ARGO mastermind Tony Mendez spoke publicly for the first time about his battle with Parkinson’s disease. Tony and his wife Jonna addressed his diagnosis and their hope that focused ultrasound might soon be a non-invasive treatment option for others. The discussion was reported by The Washington Post and media around the globe. Tony and Jonna joined the Foundation’s Council in 2013.

JOURNAL OF THERAPEUTIC ULTRASOUND

In its second year, the Journal of Therapeutic Ultrasound has already been established as a reliable and relevant source of research findings in the field. This open-access, peer-reviewed, online journal was created through a partnership with the Foundation and the International Society of Therapeutic Ultrasound to enable investigators to rapidly publish and disseminate important research. To date, the journal has published 35 translational and clinical research articles.

REACHING THE COMMUNITY
BUILDING ENGAGEMENT

87,050
website visits

15,640
YouTube views

7,890
newsletter subscribers

28%
INCREASE in Twitter followers

IN THE NEWS

“From brain to prostate, focused waves of sound can reach places a scalpel can’t, putting us on the brink of a surgical shake-up.”

“[Focused Ultrasound] redefines the very meaning of surgery.”

“FUS is a perfect example of how innovation can disrupt entire industries (for the better) and how data is helping make it happen.”

The benefits of focused ultrasound might extend well beyond restoring mobility and delivering drugs.”
OVERCOME BARRIERS
Closing the gap to patient use

In addition to advancing science, it is also important to break down barriers and ensure that focused ultrasound is available to as many patients as possible. The Foundation educates and advocates for patients and engages with regulators about the technology.

ALIGNING STAKEHOLDERS FOR REIMBURSEMENT

The Foundation hosted a productive summit in May as part of a multi-year initiative to achieve U.S. insurance coverage of focused ultrasound treatment for uterine fibroids and palliation of painful bone metastases. The more than 20 industry attendees and consultants reviewed treatment and reimbursement landscapes and explored evidence gaps to create a detailed action plan. The Foundation is optimistic that these efforts will pave the path for coverage within the next few years.

ADVOCATING FOR PROSTATE CANCER PATIENTS

Chief Scientific Officer Jessica Foley, PhD, represented the Foundation at two FDA advisory committee meetings to review focused ultrasound devices for treating prostate cancer. Foley stressed the value of patient choice and non-invasive treatment alternatives at panel sessions for EDAP and SonaCare. Both companies have devices approved outside of the U.S. to treat prostate cancer and are awaiting an FDA decision on approving their systems to treat U.S. patients.

SUPPORTING FIBROID PATIENTS

Fibroid Relief – the Foundation’s program for women with uterine fibroids – continues to serve as a popular resource for women seeking information about fibroids, including treatment options such as focused ultrasound. The organization helps women every day to find answers about treatments and seek support from others via Facebook and the website, which had a record 85,000 visits in 2014.

“Choosing Focused Ultrasound was one of the best decisions I have ever made! I returned to my normal activities as soon as I arrived home. My energy levels have raised, and my anemia is gone. It gave me my life back.”

–Marie, Fibroid patient

CULTIVATE THE NEXT GENERATION
Fostering promising researchers and students

The Foundation is dedicated to inspiring and supporting the focused ultrasound pioneers of the future. We have several programs to provide promising researchers with opportunities to collaborate with established experts and help accelerate progress.

NEW MERKIN FELLOW

Dong-guk Paeng, PhD, from Jeju National University in Korea will work with the Foundation’s technical brain program in 2015 to help lead efforts to develop safe and effective ways to expand the regions of the brain that can be accessed and treated with the technology.

The fellowship, a gift from Dr. Richard Merkin, is designed to stimulate innovation by embedding a scientist into the Foundation’s team. A renowned physician, entrepreneur, and philanthropist, Merkin is the CEO of Heritage Provider Network and co-founder of FasterCures.

GLOBAL INTERNSHIP PROGRAM DEBUTS

The Foundation launched a program for 12 interns to work with leading researchers at focused ultrasound laboratories around the globe. Jemma Brown, intern at the Institute of Cancer Research in London, was awarded travel support to the Foundation’s symposium to share her work on imaging bone and soft tissue.

RECORD FOR SUMMER INTERNS

Twelve students collaborated with Foundation staff on technical, clinical, and business projects as part of the Foundation’s Summer Internship Program. We appreciate the Claude Moore Charitable Foundation funding a portion of the 2014 program.
MOBILIZING RESOURCES
To maximize progress

The Foundation is supported through a balance of visionary individuals and public and private organizations that recognize the importance of our work. These funds have been strategically leveraged to conduct research at institutions around the world and enable the Foundation to advance the field by fostering collaboration, overcoming barriers, and cultivating the next generation.

2014 USE OF FUNDS*

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$2,310,000</td>
</tr>
<tr>
<td>Communications</td>
<td>$  796,000</td>
</tr>
<tr>
<td>Development</td>
<td>$  622,000</td>
</tr>
<tr>
<td>Symposia</td>
<td>$  520,000</td>
</tr>
<tr>
<td>External Relations</td>
<td>$  374,000</td>
</tr>
<tr>
<td>Fellowships</td>
<td>$  220,000</td>
</tr>
<tr>
<td>Reimbursement/Fibroid Relief</td>
<td>$  163,000</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>$ 5,006,000</strong></td>
</tr>
</tbody>
</table>

Numbers include fully allocated administrative expenses. Figures are unaudited.

2006–2014 USE OF FUNDS*

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$17,537,000</td>
</tr>
<tr>
<td>Communications</td>
<td>$  3,601,000</td>
</tr>
<tr>
<td>Development</td>
<td>$  3,547,000</td>
</tr>
<tr>
<td>Reimbursement/Fibroid Relief</td>
<td>$  2,291,000</td>
</tr>
<tr>
<td>Symposia</td>
<td>$  2,071,000</td>
</tr>
<tr>
<td>External Relations</td>
<td>$  1,762,000</td>
</tr>
<tr>
<td>Fellowships</td>
<td>$  1,709,000</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>$ 32,518,000</strong></td>
</tr>
</tbody>
</table>

Numbers include fully allocated administrative expenses. Figures for 2016 are unaudited.

2006–2014 SUMMARY OF EXPENSES*

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programs + Research</td>
<td>$ 24,547,000</td>
</tr>
<tr>
<td>Administration</td>
<td>$  4,424,000</td>
</tr>
<tr>
<td>Development</td>
<td>$   9,547,000</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>$ 38,518,000</strong></td>
</tr>
</tbody>
</table>

*All figures are reported on a cash basis.

Audited financials and IRS Form 990 are available upon request.
TURNING VISION

Into reality

We appreciate the generosity of our donors, who have committed more than $58 million since the Foundation was established. Thank you for the tremendous breakthroughs you have helped to make possible. Your continued support plays an outsized role in spurring innovation and building upon this progress. Below is a list of those donors who contributed funds in 2014.

In Honor of
Mr. and Mrs. Norman R. Frisbie:
Marilyn N. Seagears
Diane Heller:
Mr. and Mrs. Donald Mazzoni
Dr. Daniel P. Jordan:
Meredith Handakas

In Memory of
Dr. Peter Baginsky:
Greg and Kris Baird
Jill and Gary Moyer
Ross Carol:
Dr. Mark Carol
Jean and Chris Cullather:
Mr. John C. Cullather
Cullather Cancer Fund of
The Community Foundation
Serving Richmond and Central
Virginia

John B. Cunningham, UVA ’87:
Brothers of Zeta Psi

Wayne E. Dillon:
Mr. and Mrs. John Aiken
Dennis and Nina Barnes
Mr. Cabell Brand
Mr. F.F. Ellis III

In Memory of Caroline Murphy
Keller Winter:
Dennis and Nina Barnes
John and Betsy Lane

The promise of focused ultrasound is immense, but so are the challenges in realizing it. The Foundation has enjoyed remarkable success in bringing together donors, scientists, and clinicians, in both academia and industry, in a collaborative effort to meet those challenges.”

~Carita and Ned Kelly

Adams Charitable Foundation
Arena Foundation
Bob and Gloria Baillie
Frank and Jane Batten
David and Carolyn Beach Fund in the
Charlottesville Area Community Foundation
Anson and Debra Beard
Mr. and Mrs. F. Charles Benjamin
Mary Scott B. Belsell and John H. Belsell
Ellen and Ronald Block Family Foundation
Bill and Judy Boland
Mr. Sergio Bondi
Charles R. Brodnax
J. Peter and Nancy Brooks
W.L. Lyons Brown III Fund
Mr. Martin S. Brown
Mr. and Mrs. Charles Bryan
William F. Callow
Commonwealth of Virginia
The Joseph and Robert Connell
Memorial Foundation
Jim and Becky Craig
Croson Family Fund in the Charlottesville Area Community Foundation
Mr. and Mrs.* John Stewart Darrell
Mr. and Mrs. Albert D. Ernest
Florence Bryan Fowlkes
Mr. and Mrs. Norman Rickard Frisbie
Dr. Joe and Sally Gieck Fund in the
Charlottesville Area Community Foundation
Richard and Leslie Gilliam
Julann Griffin
Margie and Joe Grills
Molly and Robert Hardie
Herndon Foundation
Mr. and Mrs. Thomas J. Hill
Mary Buford and Frederick P. Hitz
Horton Foundation Fund in the
Charlottesville Area Community Foundation
Mr. and Mrs. Robert M. Huff
Mr. and Mrs. Anthony Ignacziak
Greg Johnson
The Johnston Family Fund of the
Manatee Community Foundation
Lou and Dan Jordan
Carita D. Corse and Edward J. Kelly III
William R. Keman, Jr. Charitable Trust
Mr. and Mrs. Donald A. King, Jr.
Gabriela and Kevin Lee
Dr. Stanley H. Levy
Mr. and Mrs. E. Charles Longley
Luminescence Foundation
J.F. Maddox Foundation
Mr. and Mrs. Ramsey Martin
Mr. and Mrs. Vincent Mastracco
Mr. and Mrs. Henry L. May IV
Janice McArdle Cancer Research Foundation
Claude Moore Charitable Foundation
Valerie Moore
Mr. and Mrs. William B. Moore
Mr. and Mrs. Wilmer J. Mountain
Wea and Sara Myhre
Elizabeth M. Neff
Paula and Rob Newcomb
Dr. and Mrs. Robert P. Nitschl
Dick and Judy Nunley
Mr. Edward P. Owens
The Mary and Daniel Loughran Foundation, Inc.
Mr. and Mrs. Robert Powell
Prince Charitable Trusts
Thomas T. Rankin
Gretchen A. Redmond
Reinsch Pierce Family Foundation
Cynthia M. Reesehe
Wyndham Robertson
Robinson Foundation
Felicia W. Rogan
The Rosenstiel Foundation
Rotgin Family Fund in the Charlottesville
Area Community Foundation
Mr. Edward M. Schaaf III
Ms. Anne B. Shumadine
VBS Foundation
Mr. and Mrs. Charles H. Seilheimer, Jr.
Mr. and Mrs. Charles H. Seilheimer III
Alicia H. Siegel
Albert H. Small, Sr.
Mr. and Mrs. C. Ray Smith
Souder Family Foundation
Mr. Cesar Stone
Virginia and John Syer
Mrs. Fay Davis Taylor
Bobby and Marilyn Thallhimer Family Fund

---

”The promise of focused ultrasound is immense, but so are the challenges in realizing it. The Foundation has enjoyed remarkable success in bringing together donors, scientists, and clinicians, in both academia and industry, in a collaborative effort to meet those challenges.”

~Carita and Ned Kelly

In Honor of
Mr. and Mrs. Norman R. Frisbie:
Marilyn N. Seagears
Diane Heller:
Mr. and Mrs. Donald Mazzoni
Dr. Daniel P. Jordan:
Meredith Handakas

In Memory of
Dr. Peter Baginsky:
Greg and Kris Baird
Jill and Gary Moyer
Ross Carol:
Dr. Mark Carol
Jean and Chris Cullather:
Mr. John C. Cullather
Cullather Cancer Fund of
The Community Foundation
Serving Richmond and Central
Virginia

John B. Cunningham, UVA ’87:
Brothers of Zeta Psi

Wayne E. Dillon:
Mr. and Mrs. John Aiken
Dennis and Nina Barnes
Mr. Cabell Brand
Mr. F.F. Ellis III

Dr. and Mrs. J. Edward Hill
Mr. and Mrs. Carlton Waskey
Mr. E.H. Will, Jr.
Mr. and Mrs. William A. Young, Jr.
George Edgar:
Mr. and Mrs. Norman Rickard Frisbie
David Heller:
Mr. and Mrs. Douglas Kinney
Mr. and Mrs. Donald Mazzoni
Kathleen Scheinfeld
Wilbur L. McBAY:
Sharon McBAY
Andrew Morgan:
Mr. and Mrs. Norman Rickard Frisbie
The Foundation’s creative use of ultrasound technology in managing Parkinson’s initially attracted us; the potential for future advancements will continue to command our attention and interest. We are proud to be associated with such an effort.

—Tony Mendez, Council Member
THE TEAM

MARK ADCOCK
Information Technology and Data Manager

AMY ATTICKS
Development Officer

RACHEL BERRY
Communications Associate

MIKE CASHMAN
Co-Director of Development

MATT EAMES, PhD
Director of Extramural Research

JESSICA FOLEY, PhD
Chief Scientific Officer

ARIK HANANEL, MD, MBA
Technical Advisor

PAIGE HARRIS
Development Officer

SARA HORTON
Director of Finance

ROBIN JONES
Director of Clinical Trials Coordination

NEAL KASSELL, MD
Chairman

SUSAN KLEES
Director of Communications

SUZANNE LeBLANG, MD
Chief Medical Officer

PAMELA MINETTI, MBA
Regional Director of Development

DAVID MOORE, MSc
Director of Technology

NICOLE PRICE
Administrative Assistant

NORA SEILHEIMER
Co-Director of Development

MARY ROSE SERAFINI
Business Manager

JOHN SNELL, PhD
Technical Director – Brain Program

PETER WEBER
Scientific Programs Associate

KURT WOERPEL, III
Chief Financial Officer

SARAH WRIGHT
Accountant

“My beloved husband was diagnosed with recurrent glioblastoma in early 2014 and ultimately became the first person in the world to undergo FUS treatment of a brain tumor through the intact skull. He attributed the months that he survived after the recurrence to the treatment. We are pleased to carry on his wish to continue progress and give hope by supporting the Foundation and its very important work.”

–Cheryl, wife of clinical trial participant

If you would like additional information or want to discuss how you can support our mission, please contact:
Mike Cashman, mcashman@fusfoundation.org
Nora Seilheimer, nseilheimer@fusfoundation.org
434.220-4993
www.fusfoundation.org
"The work the Foundation is doing will dramatically alter the future of medicine as we know it. Having already lost loved ones to cancer and other diseases, I am passionate and hopeful about what the future holds due to the efforts of the Foundation."

–Tom Johnson, Foundation supporter